GME751 (pembrolizumab biosimilar) - Sandoz
ABP 206 (nivolumab biosimilar) - Amgen
pemetrexed - Generic mfg.
erlotinib - Generic mfg.
Arfleyda (pembrolizumab biosimilar) - R-Pharm
paclitaxel - Generic mfg.
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
QL2107 (pembrolizumab biosimilar) - Qilu Pharma, Cipla
Xalkori (crizotinib) - Pfizer
gemcitabine - Generic mfg.
carboplatin - Generic mfg.
Nivocad (nivolumab biosimilar) - Biocad
Keytruda (pembrolizumab) - Merck (MSD)
cisplatin - Generic mfg.
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (clinicaltrials.gov) - Sep 24, 2026 - P=N/A | N=7458 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2026 ➔ Sep 2027 | Trial primary completion date: Sep 2026 ➔ Dec 2025 
Trial completion date • Trial primary completion date • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • CTLA4 • PD-1 • PD-L1
http://clinicaltrials.gov/ct2/show/NCT02194738
 
Sep 24, 2026
 
Prev Next